Acute Myeloid Leukemia (AML) in Children: Results of the French Trials

[1]  R. Berger,et al.  Molecular cytogenetics of childhood acute myelogenous leukaemias , 1997, European journal of haematology.

[2]  J. Buckley,et al.  Timed-sequential induction therapy improves postremission outcome in acute myeloid leukemia: a report from the Children's Cancer Group. , 1996, Blood.

[3]  R. Mayer,et al.  Intensive postremission chemotherapy in adults with acute myeloid leukemia. Cancer and Leukemia Group B. , 1994, The New England journal of medicine.

[4]  I. Bernstein,et al.  Chemotherapy for induction of remission of childhood acute myeloid leukemia followed by marrow transplantation or multiagent chemotherapy: a report from the Childrens Cancer Group. , 1994, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[5]  F. Mandelli,et al.  Prospective comparative study of bone marrow transplantation and postremission chemotherapy for childhood acute myelogenous leukemia. The Associazione Italiana Ematologia ed Oncologia Pediatrica Cooperative Group. , 1993, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[6]  J. Buckley,et al.  Impact of high-dose cytarabine and asparaginase intensification on childhood acute myeloid leukemia: a report from the Childrens Cancer Group. , 1993, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[7]  J. Klein,et al.  Treatment for acute myelocytic leukemia with allogeneic bone marrow transplantation following preparation with BuCy2. , 1991, Blood.

[8]  J. Krischer,et al.  High-dose cytarabine for intensification of early therapy of childhood acute myeloid leukemia: a Pediatric Oncology Group study. , 1991, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[9]  A. K. Srivastava,et al.  The role of timing of high‐dose cytosine arabinoside intensification and of maintenance therapy in the treatment of children with acute nonlymphocytic leukemia , 1990, Cancer.

[10]  P. Desai,et al.  Randomized multicenter trial of cytosine arabinoside with mitoxantrone or daunorubicin in previously untreated adult patients with acute nonlymphocytic leukemia (ANLL). Lederle Cooperative Group. , 1990, Leukemia.

[11]  H. Preisler,et al.  Comparison of three remission induction regimens and two postinduction strategies for the treatment of acute nonlymphocytic leukemia: a cancer and leukemia group B study. , 1987, Blood.

[12]  C. Spurr,et al.  Treatment of poor risk acute leukemia with sequential high-dose ARA-C and asparaginase. , 1984, Blood.

[13]  R. Brookmeyer,et al.  Marrow transplantation for acute nonlymphocytic leukemia after treatment with busulfan and cyclophosphamide. , 1983, The New England journal of medicine.

[14]  N. Nissen,et al.  Cytosine arabinoside with daunorubicin or adriamycin for therapy of acute myelocytic leukemia: a CALGB study. , 1982, Blood.

[15]  C. Spurr,et al.  A comparative trial of daunorubicin, cytosine arabinoside, and thioguanine, and a combination of the three agents for the treatment of acute myelocytic leukemia. , 1979, Medical and pediatric oncology.